These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8993501)

  • 1. Cellular resistance to camptothecins.
    Pommier Y; Gupta M; Valenti M; Nieves-Neira W
    Ann N Y Acad Sci; 1996 Dec; 803():60-73. PubMed ID: 8993501
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms of resistance to camptothecins.
    Saleem A; Edwards TK; Rasheed Z; Rubin EH
    Ann N Y Acad Sci; 2000; 922():46-55. PubMed ID: 11193924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Camptothecin resistance related to drug-induced down-regulation of topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks.
    Murren JR; Beidler DR; Cheng YC
    Ann N Y Acad Sci; 1996 Dec; 803():74-92. PubMed ID: 8993502
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
    Jacob S; Aguado M; Fallik D; Praz F
    Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using yeast to understand drugs that target topoisomerases.
    Nitiss JL; Rose A; Sykes KC; Harris J; Zhou J
    Ann N Y Acad Sci; 1996 Dec; 803():32-43. PubMed ID: 8993498
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin.
    Li XG; Haluska P; Hsiang YH; Bharti A; Kufe DW; Rubin EH
    Ann N Y Acad Sci; 1996 Dec; 803():111-27. PubMed ID: 8993505
    [No Abstract]   [Full Text] [Related]  

  • 7. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
    Jung LL; Zamboni WC
    Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins.
    Pommier Y
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):3-10. PubMed ID: 8633251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I.
    Champoux JJ
    Ann N Y Acad Sci; 2000; 922():56-64. PubMed ID: 11193925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ubiquitin, SUMO-1, and UCRP in camptothecin sensitivity and resistance.
    Desai SD; Mao Y; Sun M; Li TK; Wu J; Liu LF
    Ann N Y Acad Sci; 2000; 922():306-8. PubMed ID: 11193908
    [No Abstract]   [Full Text] [Related]  

  • 11. Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis.
    Li XG; Haluska P; Hsiang YH; Bharti AK; Kufe DW; Liu LF; Rubin EH
    Biochem Pharmacol; 1997 Apr; 53(7):1019-27. PubMed ID: 9174116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin.
    Hautefaye P; Cimetière B; Pierré A; Léonce S; Hickman J; Laine W; Bailly C; Lavielle G
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2731-5. PubMed ID: 12873503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of camptothecin.
    Liu LF; Duann P; Lin CT; D'Arpa P; Wu J
    Ann N Y Acad Sci; 1996 Dec; 803():44-9. PubMed ID: 8993499
    [No Abstract]   [Full Text] [Related]  

  • 14. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Burris HA; Fields SM
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid chromatin reorganization induced by topoisomerase I-mediated DNA damage.
    Sun M; Duann P; Lin CT; Zhang H; Liu LF
    Ann N Y Acad Sci; 2000; 922():340-2. PubMed ID: 11193917
    [No Abstract]   [Full Text] [Related]  

  • 16. Differences in the topoisomerase I cleavage complexes formed by camptothecin and wakayin, a DNA-intercalating marine natural product.
    Kokoshka JM; Capson TL; Holden JA; Ireland CM; Barrows LR
    Anticancer Drugs; 1996 Sep; 7(7):758-65. PubMed ID: 8949987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Camptothecins: a review of their chemotherapeutic potential.
    Ulukan H; Swaan PW
    Drugs; 2002; 62(14):2039-57. PubMed ID: 12269849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].
    Tsunoda T
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():472-5. PubMed ID: 14574938
    [No Abstract]   [Full Text] [Related]  

  • 19. Lowered phosphorylation of topoisomerase I is a direct reason for reduced sensitivity of L5178Y-S cells to camptothecin.
    Staron K; Kowalska-Loth B; Szumiel I
    Ann N Y Acad Sci; 1996 Dec; 803():321-3. PubMed ID: 8993529
    [No Abstract]   [Full Text] [Related]  

  • 20. The cell cycle effects of camptothecin.
    Darzynkiewicz Z; Bruno S; Del Bino G; Traganos F
    Ann N Y Acad Sci; 1996 Dec; 803():93-100. PubMed ID: 8993503
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.